EyePoint Sues Ocular Therapeutix Over Alleged Defamation

EyePoint Pharmaceuticals ( (EYPT) ) has provided an announcement.

On March 20, 2026, EyePoint, Inc. filed a lawsuit in Middlesex County Superior Court in Massachusetts against Ocular Therapeutix, Inc., alleging the rival disseminated false or misleading statements about EyePoint and the clinical results of its lead retinal drug candidate, DURAVYU. The complaint claims defamation, commercial disparagement, violation of Massachusetts consumer protection law, and tortious interference with business relations, as EyePoint seeks injunctive relief to halt the statements, a public retraction, and monetary damages, underscoring the intensity of competitive and reputational stakes in the ophthalmic pharmaceuticals sector.

The most recent analyst rating on (EYPT) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

Spark’s Take on EYPT Stock

According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.

EYPT scores as mixed: strong clinical/program momentum and stated runway into 2027 support the outlook, but the financial profile is a major constraint with sharply widening losses, structural near-term revenue weakness, and heavy cash burn. Technicals are broadly neutral and valuation support is limited due to negative earnings.

To see Spark’s full report on EYPT stock, click here.

More about EyePoint Pharmaceuticals

EyePoint, Inc. is a biopharmaceutical company developing ophthalmic therapies, with a focus on sustained‑release drug delivery to treat eye diseases. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is being advanced for retinal indications where long‑acting treatments can address unmet needs in the ophthalmology market.

Average Trading Volume: 1,337,338

Technical Sentiment Signal: Buy

Current Market Cap: $1.15B

Find detailed analytics on EYPT stock on TipRanks’ Stock Analysis page.